Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

ASH 2025

Lymphoma

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Multiple Myeloma (MM)

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

Blood Cancer J

Souto Filho JTD, Cantadori LO, Crusoe EQ, Hungria V, Maiolino A

doi: 10.1038/s41408-025-01413-7

CHICAGO 2026

Lymphoma

Real-world analysis demonstrates sustained responses with axi-cel in patients with R/R LBCL

Head and Neck Cancer

Trends and efficacy of definitive radiotherapy regimens for locally advanced head and neck cancer in elderly patients: A population-based analysis by the German cancer registry group

Eur J Cancer

Tinhofer I, Hofmann E, Trelinska-Finger A, Saraei T, Keilholz U, Heiland M, Letsch A, Knödler M, Beck M, Klinghammer K, Dommerich S, Wittenberg I, Reinwald F, Sackmann A, Klinkhammer-Schalke M, Zeissig SR, Weitmann K, Franke B, Schneider C, Zips D, Doll C

doi: 10.1016/j.ejca.2025.116039

Leukemia

Optimal conditioning intensity: favorable outcome of a 3-day busulfan based regimen in younger acute myeloid leukemia patients

Leuk Lymphoma

Park H, Lee JH, Lee JH, Park HS, Choi EJ, Lee KH, Hur JY, Jeong J, Cha S, Lee Y, Lee YS, Kang YA, Jeon M, Woo JM, Kang H, Choi Y

doi: 10.1080/10428194.2025.2560086

ASH 2025

Multiple Myeloma (MM)

BENEFIT: Isa-VRd achieves superior sustained MRD negativity in transplant-ineligible NDMM

CHICAGO 2026

Multiple Myeloma (MM)

SUCCESSOR-2: Addition of mezigdomide to Kd improves PFS and response rates in patients with RRMM

Multiple Myeloma (MM)

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial

Lancet Haematol

Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosiñol L, Montes YG, Bargay J, García MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garzón S, Montero FC, Cabañas V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casasús AIT, Delgado-Beltrán MP, Prieto E, Lahuerta JJ, Bladé J, San-Miguel J

doi: 10.1016/S2352-3026(25)00143-7

CHICAGO 2026

Multiple Myeloma (MM)

Oncology · Hematology

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM

Related content

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

Real-world analysis demonstrates sustained responses with axi-cel in patients with R/R LBCL

Trends and efficacy of definitive radiotherapy regimens for locally advanced head and neck cancer in elderly patients: A population-based analysis by the German cancer registry group

Optimal conditioning intensity: favorable outcome of a 3-day busulfan based regimen in younger acute myeloid leukemia patients

BENEFIT: Isa-VRd achieves superior sustained MRD negativity in transplant-ineligible NDMM

SUCCESSOR-2: Addition of mezigdomide to Kd improves PFS and response rates in patients with RRMM

DREAMM-8: Belantamab mafodotin plus Pd significantly increases sustained MRD negativity rates in patients with RRMM